Blue Apron Holdings (NYSE: APRN) posted a wider loss in the first quarter of 2020 with a year-over-year drop in revenue. The New York-based meal kit provider’s loss expanded to $20.1 million or $1.51 per share in the just-concluded quarter from a loss of $5.28 million or $0.41 per share in the year-ago quarter. Revenue dropped 28% to $101.9 million. APRN stock was down more than 15% in the before-market session.
Blue Apron said that demand for meal kits increased in the latter part of Q1 as a result of changes to consumer behavior following the implementation of stay-at-home and restaurant restriction orders throughout much of the United States in response to the COVID-19 pandemic.
For the second quarter, the company expects revenue to grow annually in high single digits percentage to about $130 million and a net loss of no more than $6 million. Blue Apron also expects to deliver a positive adjusted EBITDA of at least $5 million and a positive operating cash flow of at least $10 million in Q2.
Biotechnology company Monte Rosa Therapeutics is slated to go public this week. In a pandemic-ridden world, this industry is expanding at a healthy pace. The global biotechnology market is estimated
The healthcare sector is going through a phase of consolidation, creating fresh opportunities for emerging companies in a market that is slowly recovering from the pandemic. Several pharmaceuticals firms have
Shares of American Airlines Group (NASDAQ: AAL) have gained 42% since the beginning of this year and 50% over the past 12 months. Despite this, there is a mixed sentiment